Forum Financial Management LP Trims Holdings in Eli Lilly and Company $LLY

Forum Financial Management LP reduced its stake in Eli Lilly and Company (NYSE:LLY) by 40.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 5,123 shares of the company’s stock after selling 3,543 shares during the quarter. Forum Financial Management LP’s holdings in Eli Lilly and Company were worth $4,712,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. McMillan Office Inc. lifted its stake in Eli Lilly and Company by 0.9% during the first quarter. McMillan Office Inc. now owns 3,554 shares of the company’s stock worth $3,269,000 after purchasing an additional 33 shares in the last quarter. Drucker Wealth 3.0 LLC raised its holdings in shares of Eli Lilly and Company by 11.1% in the 1st quarter. Drucker Wealth 3.0 LLC now owns 1,330 shares of the company’s stock valued at $1,223,000 after buying an additional 133 shares during the period. Brown Miller Wealth Management LLC lifted its stake in Eli Lilly and Company by 0.4% during the 1st quarter. Brown Miller Wealth Management LLC now owns 3,971 shares of the company’s stock worth $3,652,000 after acquiring an additional 17 shares in the last quarter. Intrua Financial LLC boosted its holdings in Eli Lilly and Company by 9.8% during the 1st quarter. Intrua Financial LLC now owns 1,968 shares of the company’s stock valued at $1,810,000 after acquiring an additional 175 shares during the period. Finally, EWA LLC grew its position in Eli Lilly and Company by 35.7% in the 1st quarter. EWA LLC now owns 2,172 shares of the company’s stock valued at $1,997,000 after acquiring an additional 571 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.5%

Shares of Eli Lilly and Company stock opened at $1,199.30 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,238.00. The company has a market capitalization of $1.13 trillion, a P/E ratio of 42.60, a P/E/G ratio of 1.35 and a beta of 0.53. The company has a 50 day moving average of $1,048.18 and a 200 day moving average of $1,024.30.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue was up 55.5% on a year-over-year basis. During the same period last year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Bank of America increased their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research report on Monday, June 22nd. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,235.07.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly continues to benefit from enthusiasm around its weight-loss and diabetes franchise, with articles highlighting its dominance in the GLP-1 market and expectations for further long-term growth. Article Title
• Positive Sentiment: The FDA selected Eli Lilly for its PreCheck pilot program, which could speed reviews of new U.S. manufacturing facilities and support Lilly’s multi-billion-dollar capacity expansion. Article Title
• Positive Sentiment: Investors also reacted to Lilly’s expanding oncology reach in China and the commercialization agreement for Verzenios, which keeps Lilly involved in supply and development while adding local distribution support. Article Title
• Positive Sentiment: Separately, Lilly was highlighted in several bullish commentary pieces after hitting record highs and new 52-week highs, reinforcing momentum in the shares. Article Title
• Neutral Sentiment: Cliff Asness’ AQR Capital Management listed Lilly among its top healthcare holdings, which may support investor confidence but is not a direct operational catalyst. Article Title
• Negative Sentiment: The main pressure point is the handoff of mainland China commercialization rights for Verzenios to Innovent Biologics, which investors may view as a reduction in direct control over part of Lilly’s China business and a reason for some near-term selling. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.